Bionexus選擇以太坊而不是比特幣進行國庫策略

2025年3月5日，位於馬來西亞的Bionexus Gene Lab，通過宣布將以太坊（ETH）優先於比特幣（BTC）的決定，成為了關鍵新聞。

BioNexus Gene Lab (Nasdaq:BNXS), a publicly listed company based in Malaysia and focused on gene technology, has made the strategic decision to prioritize allocating its treasury assets into Ethereum (ETH) over Bitcoin (BTC).

Bionexus Gene Lab（NASDAQ：BNXS）是一家位於馬來西亞的公開上市公司，專注於基因技術，已做出戰略決定，優先考慮將其財政資產分配給比特幣（BTC）的以太坊（ETH）。

This decision, announced on March 5, 2025, positions BioNexus as potentially the first Nasdaq-listed institution to adjust its treasury strategy toward a primary holding of a blockchain asset.

該決定於2025年3月5日宣布，將Bionexus定位為第一個將其財政策略調整為主要持有區塊鏈資產的納斯達克上市機構。

The institution’s internal analysis, approved by its Board of Directors, identified several factors influencing their choice of Ethereum. Among these was the U.S. administration’s decision to include ETH in the government’s Crypto Strategic Reserve.

該機構的內部分析得到了董事會的批准，確定了影響以太坊選擇的幾個因素。其中包括美國政府決定將ETH納入政府的加密戰略儲備中。

Another key factor was the potential for staking on Ethereum, which allows companies to generate additional yields of 3% to 5% annually, in contrast to Bitcoin which is traditionally used as a store of value.

另一個關鍵因素是在以太坊上佔用的潛力，這使公司每年產生3％至5％的額外收益率，而比特幣通常用作價值存儲。

“Ethereum offers high liquidity, utility, and stability compared to other digital assets, positioning BGLC as a leader in blockchain-integrated corporate finance,” said Sam Tan, CEO of BioNexus.

Bionexus首席執行官Sam Tan說：“與其他數字資產相比，以太坊提供了高流動性，公用事業和穩定性，將BGLC定位為區塊鏈集成公司融資的領導者。”

The company, which had a market cap of $6 million, revenue of $2.6 million, and net income of negative $1.3 million as of September 30, 2024, is optimistic about this strategic pivot.

截至2024年9月30日，該公司的市值為600萬美元，收入為260萬美元，淨收入為130萬美元，對這一戰略樞紐非常樂觀。

This decision also follows the creation of a favorable regulatory environment for blockchain businesses in Wyoming, with the passing of the “Wyoming Stable Token Act” in March 2023 being particularly relevant.

這項決定還遵循了懷俄明州為區塊鏈業務建立一個有利的監管環境，而2023年3月的“懷俄明州穩定代幣法”的通過特別相關。

The Act allows the Wyoming Stable Token Commission to issue tokens that are exchangeable for U.S. dollars, aligning with BioNexus’s innovative, forward-thinking approach.

該法案允許懷俄明州穩定的代幣委員會發布可以美元交換的代幣，與Bionexus的創新，前瞻性的方法保持一致。

BioNexus elaborates further on Ethereum’s advantages over Bitcoin in its whitepaper titled “ETH Strategy.” The institution explains how Ethereum serves not only as digital currency but also the settlement layer for various stablecoins like Tether USD (USDT) and USD Coin (USDC).

Bionexus在其白皮書“ ETH策略”中進一步闡述了以太坊比比特幣的優勢。該機構解釋了以太坊不僅如何用作數字貨幣，而且如何使用Tether USD（USDT）和USD Coin（USDC）等各種Stablecoin的結算層。

The system handles vast transaction volumes, reported as trillions of dollars annually, bolstering its role as central to the burgeoning digital economy.

該系統處理龐大的交易量，據報導每年數万億美元，增強了其對新興數字經濟的核心作用。

Moreover, the whitepaper delves into how Ethereum’s capabilities, spanning tokenization of financial assets, decentralized payments, and enhanced regulatory compliance, render it especially appealing to banks, investment firms, and publicly traded companies. These institutions are increasingly adopting Ethereum as a component of their financial architectures.

此外，白皮書還深入研究以太坊的能力，跨越金融資產的令牌化，分散付款以及增強的監管合規性，使其對銀行，投資公司和上市公司特別有吸引力。這些機構越來越多地採用以太坊作為其金融體系結構的組成部分。

Finally, BioNexus anticipates utilizing Ethereum exchange-traded funds (ETFs) more frequently, reflecting the growing institutional acceptance of ETH. The institution’s strategy also implies support for the upcoming Ethereum upgrades, with excitement building around the Pectra update scheduled for April 2025.

最後，Bionexus預計會更頻繁地利用以太坊交換的資金（ETF），反映出ETH的製度知識不斷增長。該機構的戰略還意味著支持即將進行的以太坊升級，圍繞Pectra更新的興奮性建設計劃於2025年4月。

This update promises to improve wallet functionalities, validator operations, network performance, smart contract deployment, and account abstraction, highlighting its commitment to leveraging Ethereum’s innovation.

此更新有望改善錢包功能，驗證器操作，網絡績效，智能合同部署和帳戶抽象，強調其對利用以太坊的創新的承諾。